Search results

Filter (4 in use)

Type 2 selected

  • Remove filter for Guidance (1)
  • Remove filter for News

Status

  • Filter by Published (1)

Last updated 1 selected

  • Filter by Last 3 months
  • Filter by Last 6 months
  • Filter by Last year
  • Remove filter for Last 3 years

Guidance programme 1 selected

  • Filter by NICE guidelines (22)
  • Filter by Clinical guidelines (19)
  • Filter by Social care guidelines (4)
  • Filter by COVID-19 rapid guidelines (1)
  • Filter by Interventional procedures guidance (1)
  • Filter by Public health guidelines (1)
  • Remove filter for Technology appraisal guidance (1)

1 result for Occupational therapy

Sorted by Relevance . | Sort by Date

  • Guidance Remove Guidance filter
  • News Remove News filter
  • Last 3 years Remove Last 3 years filter
  • Technology appraisal guidance Remove Technology appraisal guidance filter
  1. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

    Type
    Technology appraisal guidance
    Published
    09 October 2019
    View recommendations for TA605
    Show all sections for TA605

    Sections for TA605

    1. Overview
    2. 1 Recommendations
    3. 2 Information about Xeomin (botulinum neurotoxin type A)
    4. 3 Committee discussion
    5. 4 Implementation
    6. 5 Appraisal committee members and NICE project team